NICE recommends Santen’s Roclanda to treat glaucoma and ocular hypertension
Primary open-angle glaucoma affects around 2% of adults aged 40 years and older in the UK
Read More
Tag: Santen
Glaucoma therapy Roclanda launched by Santen
By combining both netarsudil and latanoprost treatment, Roclanda reduces intraocular pressure
Read More
Santen launches Ducressa for post-cataract surgery
Treatment involves a combination of levofloxacin and dexamethasone for use after cataract surgery
Read More
Santen launches new educational eyecare site for patients in UK
Digital health boost as new website focuses on dry eye disease, which currently affects one in four people across the UK
Read More
Santen and Sydnexis partner on childhood myopia treatment SYD-101
Phase III trials are ongoing in Europe and the US
Read More
Oxford Biomedica, Santen enter retinal disease R&D alliance
Inherited retinal diseases are ideal candidates for gene therapy because many of the responsible genetic mutations have already been identified.
Read More
- Gobivaz approved across Europe as first Simponi biosimilar
- Poolbeg granted European patent for POLB 001
- TARA-002 shows strong early results in trial for paediatric lymphatic malformations
- Libtayo approved in EU as first adjuvant immunotherapy for high-risk CSCC
- Cellbyte raises $2.75m to slash drug launch timelines with AI
